Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R W Stephens

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Journal of Immunological Methods|February 17, 2000
Loss of ELISA specificity due to biotinylation of monoclonal antibodiesG Høyer-Hansen, M J Hamers, A N Pedersen, et al.
The Journal of Rheumatology|December 1, 1975
The origins and relative distribution of polysaccharidases in rheumatoid and osteoarthritic fluidsR W Stephens, P Ghosh, T K Taylor, et al.
Gynecologic Oncology|August 25, 2001
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseasesR Riisbro, R W Stephens, N Brünner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancerM N Holten-Andersen, R W Stephens, H J Nielsen, et al.
Clinical Chemistry|August 3, 1999
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patientsA N Pedersen, N Brünner, G Høyer-Hansen, et al.
Journal of Immunological Methods|April 11, 1997
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISAA N Pedersen, G Høyer-Hansen, N Brünner, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 23, 1999
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevanceC F Sier, N Sidenius, A Mariani, et al.
The EMBO Journal|September 2, 1999
Functional overlap between two classes of matrix-degrading proteases in wound healingL R Lund, J Romer, T H Bugge, et al.
Breast Cancer Research and Treatment|December 1, 2001
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastatC Holst-Hansen, J A Low, R W Stephens, et al.
Biochemistry|August 25, 1992
Heparin binding to the urokinase kringle domainR W Stephens, A M Bokman, H T Myöhänen, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Journal of Immunological Methods|February 17, 2000
Loss of ELISA specificity due to biotinylation of monoclonal antibodiesG Høyer-Hansen, M J Hamers, A N Pedersen, et al.
The Journal of Rheumatology|December 1, 1975
The origins and relative distribution of polysaccharidases in rheumatoid and osteoarthritic fluidsR W Stephens, P Ghosh, T K Taylor, et al.
Gynecologic Oncology|August 25, 2001
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseasesR Riisbro, R W Stephens, N Brünner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancerM N Holten-Andersen, R W Stephens, H J Nielsen, et al.
Clinical Chemistry|August 3, 1999
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patientsA N Pedersen, N Brünner, G Høyer-Hansen, et al.
Journal of Immunological Methods|April 11, 1997
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISAA N Pedersen, G Høyer-Hansen, N Brünner, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 23, 1999
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevanceC F Sier, N Sidenius, A Mariani, et al.
The EMBO Journal|September 2, 1999
Functional overlap between two classes of matrix-degrading proteases in wound healingL R Lund, J Romer, T H Bugge, et al.
Breast Cancer Research and Treatment|December 1, 2001
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastatC Holst-Hansen, J A Low, R W Stephens, et al.
Biochemistry|August 25, 1992
Heparin binding to the urokinase kringle domainR W Stephens, A M Bokman, H T Myöhänen, et al.
Pageof 10